GeneDx Holdings
WGS
68.53
-2.99
-4.18%
GeneDx Holdings
US · WGS
#2702 by market cap
Listed 1970
68.53
-2.99
-4.18%
Live - 5344 symbols - heartbeat 503s ago
· 2026-10-08 07:25
Pre-market
67.05
-2.16%
After-hours
68.53
0.00%
Overnight
68.50
-0.04%
- Market cap
- 2.04B
- P/E (TTM)i
- -18.93
- P/Bi
- 8.37
- EPSi
- -0.73
- Div yieldi
- 0.00%
- 52W posi
- 26%
Reader sentiment
Are you bullish or bearish on WGS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.12, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +39.97% YoY
Margins
- Gross margin
- 69.74%
- Operating margin
- -3.06%
- Net margin
- -4.92%
Key ratios & quality
- Enterprise valuei
- 1.93B
- Altman Z-Scorei
- 3.12
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 196.17M | 179.32M | 212.20M | 234.69M | 202.57M | 305.45M | 427.54M |
| Gross profit | 82.79M | 4.03M | -16.60M | -26.75M | 90.01M | 194.40M | 298.17M |
| Selling & admin expenses | 68.84M | 163.93M | 318.73M | 338.24M | 199.98M | 171.89M | 239.22M |
| Research & development | 34.91M | 72.70M | 105.16M | 86.20M | 58.27M | 45.72M | 72.03M |
| Operating profit | -30.41M | -241.99M | -446.15M | -457.51M | -170.19M | -23.21M | -13.08M |
| Pretax profit | -29.70M | -241.34M | -245.39M | -598.03M | -176.69M | -52.63M | -21.14M |
| Tax | 0 | 0 | 0 | -49.05M | -926.00K | -343.00K | -116.00K |
| Net profit | -29.70M | -241.34M | -245.39M | -548.98M | -175.77M | -52.29M | -21.02M |
| Basic EPS | -4 | -33 | -75 | -54 | -7 | -2 | -1 |
| Diluted EPS | -4.50 | -33.16 | -74.91 | -53.63 | -7.23 | -1.94 | -0.73 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 87.12M | 102.69M | 116.74M | 120.99M | 102.25M | 114.44M |
| Gross profit | 58.48M | 70.90M | 84.53M | 84.27M | 68.21M | 78.24M |
| Selling & admin expenses | 50.45M | 46.10M | 67.20M | 76.13M | 74.59M | 72.73M |
| Research & development | 12.58M | 15.08M | 19.83M | 24.54M | 19.80M | 19.66M |
| Operating profit | -4.55M | 9.03M | -3.25M | -14.24M | -26.18M | -15.24M |
| Pretax profit | -6.08M | 10.56M | -7.39M | -18.23M | -62.42M | -18.26M |
| Tax | 447.00K | -246.00K | 247.00K | -564.00K | 897.00K | -518.00K |
| Net profit | -6.53M | 10.81M | -7.64M | -17.67M | -63.32M | -17.74M |
| Basic EPS | 0 | 0 | 0 | -1 | -2 | -1 |
| Diluted EPS | -0.23 | 0.36 | -0.27 | -0.61 | -2.16 | -0.60 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | -- | 174.11M | 483.54M | 212.62M | 182.34M | 197.97M | 268.29M |
| Cash & ST investments | -- | 108.13M | 400.57M | 123.93M | 130.15M | 141.19M | 171.28M |
| Inventory | -- | 24.96M | 33.46M | 13.67M | 8.78M | 10.65M | 13.95M |
| Total assets | -- | 251.64M | 554.09M | 490.94M | 418.76M | 419.38M | 523.71M |
| Total current liabilities | -- | 73.44M | 101.28M | 144.30M | 58.82M | 54.82M | 108.91M |
| Short-term debt | -- | 5.28M | -- | 10.87M | 3.65M | 4.55M | 8.95M |
| Long-term debt | -- | 18.97M | 11.00M | 6.25M | 52.69M | 51.91M | 48.18M |
| Total liabilities | -- | 581,693,000.00 | 165,990,000.00 | 237,237,000.00 | 190,739,000.00 | 174,133,000.00 | 215,528,000.00 |
| Total equity | -- | -330.05M | 388.10M | 253.71M | 228.02M | 245.25M | 308.18M |
| Retained earnings | -- | -330.05M | -575.44M | -1.12B | -1.30B | -1.35B | -1.37B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 225.82M | 204.84M | 237.58M | 268.29M | 270.63M | 246.36M |
| Cash & ST investments | 159.16M | 134.56M | 155.08M | 171.28M | 170.69M | 132.55M |
| Inventory | 12.66M | 11.93M | 10.57M | 13.95M | 12.24M | 17.82M |
| Total assets | 446.43M | 463.86M | 493.90M | 523.71M | 506.30M | 481.49M |
| Total current liabilities | 69.54M | 71.41M | 87.62M | 108.91M | 87.64M | 74.63M |
| Short-term debt | 3.12M | 3.08M | 4.43M | 8.95M | 5.13M | 5.71M |
| Long-term debt | 51.79M | 51.68M | 51.58M | 48.18M | 96.73M | 96.84M |
| Total liabilities | 189,025,000.00 | 186,730,000.00 | 201,644,000.00 | 215,528,000.00 | 252,177,000.00 | 237,265,000.00 |
| Total equity | 257.41M | 277.13M | 292.26M | 308.18M | 254.12M | 244.22M |
| Retained earnings | -1.36B | -1.35B | -1.36B | -1.37B | -1.44B | -1.45B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -18.73M | -93.13M | -190.43M | -319.16M | -180.15M | -28.50M | 33.28M |
| Depreciation & amortization | 6.41M | 11.73M | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| Free cash flow | -34.18M | -125.10M | -211.22M | -333.48M | -185.86M | -33.99M | 14.26M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 442.68M | 197.66M | 143.00M | 46.50M | 46.70M |
| Ending cash balance | 115.01M | 118.96M | 401.47M | 138.30M | 100.67M | 86.20M | 105.99M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 10.18M | 10.42M | 15.77M | -3.09M | -32.41M | -28.98M |
| Depreciation & amortization | 5.68M | 6.19M | 6.47M | 6.88M | 6.81M | 6.71M |
| Free cash flow | 4.05M | 8.05M | 9.60M | -7.44M | -38.86M | -39.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 13.89M | 1.13M | 11.80M | 19.87M | 97.47M | -95.21M |
| Ending cash balance | 100.69M | 75.11M | 96.96M | 105.99M | 94.92M | 61.31M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -845.41 | -171.07 | -72.97 | -22.10 | -7.60 |
| ROA %i | -- | -95.91 | -60.91 | -105.06 | -38.64 | -12.48 | -4.46 |
| ROIC %i | -- | -- | -357.02 | -145.88 | -51.80 | -14.75 | -5.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -223.83 |
| EBIT margin %i | -14.74 | -133.21 | -114.31 | -253.45 | -84.02 | -7.60 | -3.06 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 3.34 |
| Current ratioi | -- | 2.37 | 4.77 | 1.47 | 3.10 | 3.61 | 2.46 |
| Quick ratioi | -- | 1.91 | 4.22 | 1.16 | 2.77 | 3.26 | 2.26 |
| Debt / assetsi | -- | 17.89 | 1.99 | 15.71 | 28.48 | 27.99 | 21.61 |
| LT debt / equityi | -- | -- | 2.83 | 26.12 | 50.71 | 46.01 | 33.82 |
| Interest coveragei | -36.94 | -96.55 | -85.56 | -185.48 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 6.16 | 4.15 | 12.91 | 22.13 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -16.61 | 0.60 | 0.84 | -7.60 | -30.42 | -40.80 |
| ROA %i | -9.17 | 0.33 | 0.46 | -4.46 | -16.33 | -22.50 |
| ROIC %i | -11.06 | 0.40 | 0.57 | -5.37 | -19.59 | -26.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2.71 | 8.53 | 2.48 | -3.06 | -15.66 | -21.52 |
| FCF / sales %i | -- | 0.23 | 3.85 | 3.34 | -- | -- |
| Current ratioi | 3.25 | 2.87 | 2.71 | 2.46 | 3.09 | 3.30 |
| Quick ratioi | 2.95 | 2.56 | 2.47 | 2.26 | 2.83 | 2.90 |
| Debt / assetsi | 25.72 | 24.66 | 22.91 | 21.61 | 33.22 | 34.77 |
| LT debt / equityi | 43.40 | 40.16 | 37.20 | 33.82 | 64.17 | 66.21 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
GeneDx100.00%
Quote time 2026-10-08 07:25:32 · For reference only, not investment advice and not tailored to your situation.